Literature DB >> 17486396

Increased incidence of idiopathic persistent pulmonary hypertension in Down syndrome neonates.

C L Cua1, A Blankenship, A L North, J Hayes, L D Nelin.   

Abstract

Down syndrome (DS) patients have an increased risk of developing pulmonary hypertension later in life compared to age-matched controls. The goal of this study was to determine if the incidence of persistent pulmonary hypertension of the newborn (PPHN) is also higher in neonatal DS patients compared to the general population. A retrospective chart review of DS patients admitted during a 3-year period to the neonatal intensive care unit was performed. DS patients with meconium aspiration syndrome, pulmonary infections, or pulmonary space-occupying lesions were excluded. DS patients were divided into four groups based on treatment and consisted of no intervention (A), supplemental oxygen (B,) mechanical ventilation use (C), and inhaled nitric oxide administration (D). Group D was defined as having PPHN. z test of the difference between sample and known population, chi-square, t-test, and analysis of variance with Tukey adjusted post hoc test were used for analysis. p<0.05 was considered significant. A total of 58 patients met inclusion criteria. Twenty-four DS patients were in group A, 17 in group B, 10 in group C, and 7 in group D. There was no difference between the four groups for gender (males: 10, 5, 5, and 5, respectively), gestational age (36.4, 38.2, 36.4, and 36.4 weeks, respectively), weight (2.8, 3.0, 2.4, and 3.0 kg, respectively), or the presence of congenital heart defects (17, 10, 6, and 1, respectively). The estimated number of DS patients born in the state of Ohio during this period was 598; therefore, the incidence of PPHN in DS was 1.2%. The reported incidence of PPHN is 0.1%. The reported incidence of PPHN was significantly lower versus the incidence of PPHN in DS (z=2.7, p=0.007). It was concluded that DS patients have an increased incidence of PPHN compared to historical controls regardless of baseline demographics.

Entities:  

Mesh:

Year:  2007        PMID: 17486396     DOI: 10.1007/s00246-006-0011-6

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  27 in total

1.  Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes.

Authors:  M C Walsh-Sukys; J E Tyson; L L Wright; C R Bauer; S B Korones; D K Stevenson; J Verter; B J Stoll; J A Lemons; L A Papile; S Shankaran; E F Donovan; W Oh; R A Ehrenkranz; A A Fanaroff
Journal:  Pediatrics       Date:  2000-01       Impact factor: 7.124

2.  Endothelial nitric oxide synthase genotype modulates the improvement of coronary blood flow by pravastatin: a placebo-controlled PET study.

Authors:  Tarja A Kunnas; Terho Lehtimäki; Reijo Laaksonen; Erkki Ilveskoski; Tuula Janatuinen; Risto Vesalainen; Pirjo Nuutila; Pekka J Karhunen; Juhani Knuuti; Seppo T Nikkari
Journal:  J Mol Med (Berl)       Date:  2002-11-22       Impact factor: 4.599

3.  Chronic upper airway obstruction and pulmonary hypertension in Down's syndrome.

Authors:  T W Rowland; L G Nordstrom; M S Bean; H Burkhardt
Journal:  Am J Dis Child       Date:  1981-11

4.  The pulmonary vascular bed in children with Down syndrome.

Authors:  J Chi TPL?Krovetz
Journal:  J Pediatr       Date:  1975-04       Impact factor: 4.406

5.  Clinical characteristics and follow up of Down syndrome infants without congenital heart disease who presented with persistent pulmonary hypertension of newborn.

Authors:  Prakesh S Shah; Jonathan Hellmann; Ian Adatia
Journal:  J Perinat Med       Date:  2004       Impact factor: 1.901

6.  Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction.

Authors:  Y Shimasaki; H Yasue; M Yoshimura; M Nakayama; K Kugiyama; H Ogawa; E Harada; T Masuda; W Koyama; Y Saito; Y Miyamoto; Y Ogawa; K Nakao
Journal:  J Am Coll Cardiol       Date:  1998-06       Impact factor: 24.094

7.  BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease.

Authors:  K E Roberts; J J McElroy; W P K Wong; E Yen; A Widlitz; R J Barst; J A Knowles; J H Morse
Journal:  Eur Respir J       Date:  2004-09       Impact factor: 16.671

8.  AT1 receptor blockade limits myocardial injury and upregulates AT2 receptors during reperfused myocardial infarction.

Authors:  Bodh I Jugdutt; Vijayan Menon
Journal:  Mol Cell Biochem       Date:  2004-05       Impact factor: 3.396

9.  Comparison of hemodynamic data before and after corrective surgery for Down's syndrome and ventricular septal defect.

Authors:  T Kawai; Y Wada; T Enmoto; K Nishiyama; K Kitaura; S Sato; T Oka
Journal:  Heart Vessels       Date:  1995       Impact factor: 2.037

10.  Pulmonary hypoplasia in Down's syndrome.

Authors:  T P Cooney; W M Thurlbeck
Journal:  N Engl J Med       Date:  1982-11-04       Impact factor: 91.245

View more
  27 in total

1.  Down syndrome patients with pulmonary hypertension have elevated plasma levels of asymmetric dimethylarginine.

Authors:  Clifford L Cua; Lynette K Rogers; Louis G Chicoine; Molly Augustine; Yi Jin; Patricia L Nash; Leif D Nelin
Journal:  Eur J Pediatr       Date:  2010-12-01       Impact factor: 3.183

2.  NICU management and outcomes of infants with trisomy 21 without major anomalies.

Authors:  Sarah McAndrew; Krishna Acharya; T Hang Nghiem-Rao; Steven Leuthner; Reese Clark; Joanne Lagatta
Journal:  J Perinatol       Date:  2018-05-25       Impact factor: 2.521

3.  Assessment of cardiac function in absence of congenital and acquired heart disease in patients with Down syndrome.

Authors:  Sevket Balli; Ilker Kemal Yucel; Ayse Esin Kibar; Ibrahim Ece; Eylem Sen Dalkiran; Sukru Candan
Journal:  World J Pediatr       Date:  2016-04-08       Impact factor: 2.764

4.  Differences in mortality characteristics in neonates with Down's syndrome.

Authors:  C L Cua; U Haque; S Santoro; L Nicholson; C H Backes
Journal:  J Perinatol       Date:  2017-01-12       Impact factor: 2.521

5.  Hepatic failure, neonatal hemochromatosis and porto-pulmonary hypertension in a newborn with trisomy 21--a case report.

Authors:  Erin Neil; Josef Cortez; Aparna Joshi; Erawati V Bawle; Janet Poulik; Mark Zilberman; Mohammad F El-Baba; Beena G Sood
Journal:  Ital J Pediatr       Date:  2010-05-18       Impact factor: 2.638

Review 6.  The Robyn Barst Memorial Lecture: Differences between the fetal, newborn, and adult pulmonary circulations: relevance for age-specific therapies (2013 Grover Conference series).

Authors:  Steven H Abman; Christopher Baker; Jason Gien; Peter Mourani; Csaba Galambos
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

7.  Decreased OLA1 (Obg-Like ATPase-1) Expression Drives Ubiquitin-Proteasome Pathways to Downregulate Mitochondrial SOD2 (Superoxide Dismutase) in Persistent Pulmonary Hypertension of the Newborn.

Authors:  Adam Schultz; Olubunmi A Olorundami; Ru-Jeng Teng; Jason Jarzembowski; Zheng-Zheng Shi; Suresh N Kumar; Kirkwood Pritchard; Girija G Konduri; Adeleye J Afolayan
Journal:  Hypertension       Date:  2019-09-03       Impact factor: 10.190

Review 8.  Sleep Disturbances in Neurodevelopmental Disorders.

Authors:  Althea Robinson-Shelton; Beth A Malow
Journal:  Curr Psychiatry Rep       Date:  2016-01       Impact factor: 5.285

9.  Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension.

Authors:  Rachel Damico; Todd M Kolb; Lidenys Valera; Lan Wang; Traci Housten; Ryan J Tedford; David A Kass; Nicholas Rafaels; Li Gao; Kathleen C Barnes; Raymond L Benza; James L Rand; Rizwan Hamid; James E Loyd; Ivan M Robbins; Anna R Hemnes; Wendy K Chung; Eric D Austin; M Bradley Drummond; Stephen C Mathai; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2015-01-15       Impact factor: 21.405

10.  Usefulness of Postnatal Echocardiography in Patients with Down Syndrome with Normal Fetal Echocardiograms.

Authors:  Amy Cooper; Kacy Sisco; Carl H Backes; Marc Dutro; Ruth Seabrook; Stephanie L Santoro; Clifford L Cua
Journal:  Pediatr Cardiol       Date:  2019-09-20       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.